What is your current guidance about whether and/or how and when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine?

What is your current guidance about whether and/or how and when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine?

What is your current guidance about whether and/or how and when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Prof. Matthew Krebs, MD, PhD

Prof. Matthew Krebs, MD, PhD

Clinical Senior Lecturer
Experimental Cancer Medicine
Honorary Consultant
Medical Oncology
The University of Manchester
Greater Manchester, UK